In vivo treatment of tyrosinaemia with hypercompact Cas12f1

Cell Discovery

Correspondence

Hainan Zhang¹  Yingsi Zhou¹  Yuanhua Liu²  Xinyu Liu²  Xiali Yang²  Chang Zhang²  Guoling Li²  Hui Yang³  Ruochen Guo⁴  Xiaozhi Sun⁵  Xiaoyin Zhang⁶  Zhifang Li⁶  Rongrong Yang⁶  Xiaona Huo⁶  Chunlong Xu⁷ 

[1] HuidaGene Therapeutics Inc, Shanghai, China;Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;Shanghai Center for Brain Science and Brain-Inspired Technology, Shanghai, China;HuidaGene Therapeutics Inc, Shanghai, China;Lingang Laboratory, Shanghai, China;Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;Lingang Laboratory, Shanghai, China;School of Life Sciences and Technology, ShanghaiTech University, Shanghai, China;Lingang Laboratory, Shanghai, China;Shanghai Center for Brain Science and Brain-Inspired Technology, Shanghai, China;Lingang Laboratory, Shanghai, China;Shanghai Center for Brain Science and Brain-Inspired Technology, Shanghai, China;School of Life Sciences and Technology, ShanghaiTech University, Shanghai, China;

关键词: ;   

DOI  :  10.1038/s41421-023-00554-y

 received in 2022-11-16, accepted in 2023-04-18,  发布年份 2023

来源: Springer

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 2

Fig. 3